High materiality7/10
Dyne Therapeutics price target lowered to $45 from $47 at Morgan Stanley
Why it may matterVerify against the original reporting
Bullish setup
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Target set at $45; posted price $24.64; firm Morgan Stanley; upside remains despite downgrade.
- Target $45; Price $24.64; Morgan Stanley; +0.31 since signal.
Key facts
- 01
Target: $45
- 02
Posted price: $24.64
- 03
Analyst firm: Morgan Stanley
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.